OncoC4 Expands Scientific Advisory Board with Appointment of Heather A. Wakelee, MD, FASCO
April 02, 2024 08:00 ET
|
OncoC4, Inc.
Dr. Wakelee is a world-renowned expert in the research and treatment of lung cancerOncoC4’s SAB now includes 6 distinguished scientists, industry experts, and key opinion leaders in oncology and...
HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC
March 27, 2024 20:00 ET
|
HUTCHMED (China) Limited
— Oral presentation at the European Lung Cancer Congress 2024 of Phase IIIb data demonstrating median PFS of 13.7 months and median OS not reached in treatment-naïve patients — — If approved, would...
IO Biotech Announces 2023 Fourth-Quarter and Year-End Results
March 05, 2024 16:40 ET
|
IO Biotech
IO Biotech Announces 2023 Fourth-Quarter and Year-End Results
BioAtla Presented Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL Event
December 05, 2023 08:00 ET
|
BioAtla, Inc.
Results from the Phase 2 BA3011 clinical non-small cell lung cancer (NSCLC) study demonstrated promising clinical benefits in heavily pre-treated non-squamous histology patients across key endpoints ...
KRAS Inhibitors Market Current Trends and Future Scope Analysis Report
December 05, 2023 06:45 ET
|
InsightAce Analytic Pvt. LTd.
Jersey City, NJ, Dec. 05, 2023 (GLOBE NEWSWIRE) -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global KRAS Inhibitors Market - (By Cancer Type (Lung...
Apollomics Presents Interim Data from Two Ongoing Phase 2 Clinical Trials with Vebreltinib in NSCLC Patients with MetExon14 Skipping Mutation
December 04, 2023 07:00 ET
|
Apollomics Inc.
Treatment of NSCLC patients with MetExon14 skipping mutation with and without co-occurring MET amplification, reflecting “real-world”1 setting FOSTER CITY, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) --...
BioAtla to Host Virtual KOL Event to Review IASLC Data on BA3011 in NSCLC
November 28, 2023 08:00 ET
|
BioAtla, Inc.
SAN DIEGO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
Apollomics Announces Presentation of Vebreltinib Data at the 2023 IASLC North America Conference on Lung Cancer (NACLC)
November 28, 2023 07:00 ET
|
Apollomics Inc.
FOSTER CITY, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to...
IO Biotech Announces 2023 Third Quarter Results
November 13, 2023 08:12 ET
|
IO Biotech
IO Biotech Announces 2023 Third Quarter Results
Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2023 Financial Results and Corporate Updates
November 07, 2023 16:01 ET
|
Iovance Biotherapeutics, Inc.
FDA Priority Review of Biologics License Application (BLA) on Track for Lifileucel in Advanced Melanoma with Prescription Drug User Fee Act Action (PDUFA) Date of February 24, 2023 ...